GeneSight Test Reduces Psychiatric Hospitalizations in Depression Patients
A study published in the Journal of Clinical Psychopharmacology revealed that patients with major depressive disorder experienced fewer psychiatric...
Jon Napitupulu
Achieve Life Sciences Publishes Smoking Cessation Trial Results in JAMA
Achieve Life Sciences announced complete results from its ORCA-3 trial, published in JAMA Internal Medicine, demonstrating cytisinicline’s efficacy in...
FDA Grants Orphan Drug Designation to TPST-1495 for FAP Treatment
Tempest Therapeutics announced that the FDA granted Orphan Drug Designation to TPST-1495 for treating Familial Adenomatous Polyposis (FAP). TPST-1495...
Tovecimig Dosed in First-Line Biliary Tract Cancer Trial
Compass Therapeutics has initiated the first patient dosing in an Investigator Sponsored Trial (IST) at MD Anderson Cancer Center....
Elutia Launches Elupro™ Registry Study
Elutia Inc. launched a clinical study to gather real-world data on patient outcomes using EluPro, its FDA-cleared antibiotic-eluting bioenvelope...
Regeneron Eylea HD 8 mg Update: Biologics License Application
Regeneron Pharmaceuticals received a Complete Response Letter (CRL) from the FDA regarding its application to extend EYLEA HD’s dosing...
Sernova Secures $4M Loan for Clinical Development
Sernova Biotherapeutics secured a CAD$4 million term loan from Navigate Private Yield Fund LP III. The loan, which matures...
Non-Invasive Vagus Nerve Stimulation: Effective Concussion Treatment
ElectroCore, Inc. announced positive data from a study presented at the 2025 International Brain Injury Association World Congress, showing...
Namodenoson’s Compassionate Use For Pancreatic Cancer Sought By US Medical Centers
Can-Fite BioPharma announced that major U.S. medical centers are requesting FDA compassionate use approval for Namodenoson, its pancreatic cancer...
Alector Announces Phase 2 Trial Completion for Early Alzheimer’s Disease
Alector and GSK have completed enrollment in their Phase 2 PROGRESS-AD trial, evaluating AL101/GSK4527226 for early-stage Alzheimer’s diseaseAlzheimer’s disease....